Navigating the Next Wave of Clinical Trials for Alzheimer’s Disease Research
DOI :
https://doi.org/10.18192/uojm.v16iS1.7815Mots-clés :
Alzheimer’s disease, Clinical Trials, Biomarkers, Disease-modifying Therapies, Patient-centered OutcomesRésumé
Recent advances in Alzheimer’s disease research have reshaped how clinical trials are designed and interpreted, particularly through the use of targeted monoclonal antibodies, biomarker-guided enrollment, and novel drug delivery strategies. Evidence from recent clinical and translational studies highlights a growing gap between biological target engagement and meaningful improvements in cognition, functional independence, and quality of life. Although emerging therapies demonstrate measurable effects on disease biology, their clinical impact remains modest and inconsistent. Ensuring that mechanistic innovation aligns with patient-centered outcomes will be essential for translating these advances into meaningful therapeutic progress.
Références
1. 2025 Alzheimer's disease facts and figures. Alzheimers Dement. 2025 Apr 29;21(4):e70235. doi: 10.1002/alz.70235. PMCID: PMC12040760.
2. Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311-23. doi: 10.3233/JAD-2010-1221. PMID: 20061647; PMCID: PMC2813509.
3. Alkhalifa AE, Al Mokhlf A, Ali H, Al-Ghraiybah NF, Syropoulou V. Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection. J Pers Med. 2025 Sep 15;15(9):437. doi: 10.3390/jpm15090437. PMID: 41003140; PMCID: PMC12470750.
4. Knopman DS. Lecanemab reduces brain amyloid-β and delays cognitive worsening. Cell Rep Med. 2023 Mar 21;4(3):100982. doi: 10.1016/j.xcrm.2023.100982. PMID: 36948153; PMCID: PMC10040446.
5. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PMID: 36449413.
6. Jayaprakash N, Elumalai K. Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application. Chronic Dis Transl Med. 2024 Dec 16;11(2):105-116. doi: 10.1002/cdt3.155. PMID: 40486952; PMCID: PMC12142702.
7. Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022 Oct 1;79(10):1015-1024. doi: 10.1001/jamaneurol.2022.2793. PMID: 36094645; PMCID: PMC9468959.
8. Smith EE, Phillips NA, Feldman HH, Borrie M, Ganesh A, Henri-Bhargava A, et al. Canadian Consortium on Neurodegeneration in Aging Investigators. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research. J Prev Alzheimers Dis. 2025 Mar;12(3):100068. doi: 10.1016/j.tjpad.2025.100068. Epub 2025 Jan 31. PMID: 39893139; PMCID: PMC12184013.
9. Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol. 2023 Dec;19(12):715-736. doi: 10.1038/s41582-023-00883-2. Epub 2023 Oct 24. PMID: 37875627; PMCID: PMC10965012.
10. Klein G, Rabinovici GD, Zetterberg H, Tonietto M, Bittner T, Rukina D, et al. Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer’s disease. Alzheimers Dement. 2025 Dec 25;21(Suppl 5):e104288. doi: 10.1002/alz70859_104288. PMCID: PMC12740797.
11. Smith J, Mummery CJ, Cummings JL, Rabinovici GD, Salloway S, Sperling RA, et al. TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer’s disease. Alzheimers Dement. 2025 Dec 26;21(Suppl 5):e104294. doi: 10.1002/alz70859_104294. PMCID: PMC12741723.
12. Zhang Y, Bi K, Zhou L, Wang J, Huang L, Sun Y, et al. Advances in Blood Biomarkers for Alzheimer's Disease: Ultra-Sensitive Detection Technologies and Impact on Clinical Diagnosis. Degener Neurol Neuromuscul Dis. 2024 Jul 30;14:85-102. doi: 10.2147/DNND.S471174. PMID: 39100640; PMCID: PMC11297492.
13. Pascoal TA, Aguzzoli CS, Lussier FZ, Crivelli L, Suemoto CK, Fortea J, et al. Insights into the use of biomarkers in clinical trials in Alzheimer's disease. EBioMedicine. 2024 Oct;108:105322. doi: 10.1016/j.ebiom.2024.105322. Epub 2024 Oct 3. PMID: 39366844; PMCID: PMC11663755.
14. Stoeckel LE, Fazio EM, Hardy KK, Kidwiler N, McLinden KA, Williams B. Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials. Alzheimers Dement (N Y). 2025 Feb 19;11(1):e70058. doi: 10.1002/trc2.70058. PMID: 39975465; PMCID: PMC11837731.
15. Stirland LE, Choate R, Zanwar PP, Zhang P, Watermeyer TJ, Valletta M, et al. Multimorbidity in dementia: Current perspectives and future challenges. Alzheimers Dement. 2025 Aug;21(8):e70546. doi: 10.1002/alz.70546. PMID: 40755143; PMCID: PMC12319240.
Téléchargements
Publié-e
Comment citer
Numéro
Rubrique
Licence
© Rachel Sudhakar 2026
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
- Les auteurs qui publient dans le JMUO gardent les droits d’auteur de leurs articles, incluant tous les brouillons et la copie finale publiée dans le journal
- Bien que le JMUO n’a pas les droits d’auteur des articles soumis, en acceptant de publier dans le JMUO, les auteurs donnent le droit au journal d’être les premiers à publier et à distribuer leurs articles.
- Par la suite, les auteurs peuvent soumettre leurs documents à d’autres publications, incluant des revues ou des livres, avec un remerciement de leur première publication dans le JMUO
- Des copies du JMUO seront distribuées à la fois sous format papier et en ligne, et tous les matériaux seront accessibles au public en ligne. Le journal n’a pas de responsabilité légale par rapport à la distribution publique du contenu.
- Prière de vous assurer que tous les auteurs, les coauteurs et les investigateurs
- Le contenu est rendu disponible sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
